Anesiva's first product launch, Zingo
This article was originally published in Scrip
The US biopharmaceutical firm Anesivahas launched its needle-free intradermal lidocaine system, Zingo, in the US, for reducing pain associated with taking blood and inserting iv lines in children aged three to 18 years. It is the company's first product launch.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
With a candidate COVID-19 therapy in clinical development, the UK’s Synairgen has raised $101m on the UK’s AIM to support clinical studies and manufacturing plans.
Although top-line efficacy results from a small study in critically ill patients with COVID-19 suggest there are therapeutic benefits associated with Relief Therapeutics/NeuroRx’s RLF-100 (aviptadil), further data are awaited from the results of a randomized clinical trial, expected later this year.